# To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Hepatic Function and Hepatic Impairment.

> **NCT04831944** · PHASE1 · COMPLETED · sponsor: **Incyte Corporation** · enrollment: 21 (actual)

## Conditions studied

- Advanced Malignancies

## Interventions

- **DRUG:** parsaclisib

## Key facts

- **NCT ID:** NCT04831944
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-29
- **Primary completion:** 2022-03-10
- **Final completion:** 2022-03-11
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2022-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04831944

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04831944, "To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Hepatic Function and Hepatic Impairment.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04831944. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*